Key Financial Figures - Standalone (₹ in lacs)
Quarterly Performance
| Period | Revenue from Operations | Other Income | Total Revenue | Net Profit |
| Q4 FY26 (Mar 2026) | 6,581.32 | 4.67 | 6,585.99 | 90.10 |
| Q3 FY26 (Dec 2025) | 1,015.97 | 14.24 | 1,030.21 | 15.80 |
| Q4 FY25 (Mar 2025) | 2,104.95 | 14.03 | 2,118.98 | 58.11 |
Annual Performance
| Period | Revenue from Operations | Other Income | Total Revenue | Net Profit |
| FY 2025-26 | 8,545.89 | 50.92 | 8,596.81 | 116.55 |
| FY 2024-25 | 3,244.70 | 57.11 | 3,301.81 | 87.60 |
Expense Breakdown FY26 (₹ in lacs)
- Purchase of Stock in trade: 8,258.74
- Employees benefits expense: 49.79
- Finance Cost: 2.61
- Depreciation and amortisation: 6.94
- Other Expenses: 117.36
Balance Sheet Position (Standalone)
| Item | As at 31-Mar-2026 | As at 31-Mar-2025 |
| Total Assets | 9,650.10 | 4,016.60 |
| Non-current assets | 4,880.27 | 2,636.34 |
| Current assets | 4,769.83 | 1,380.26 |
| Equity and Liabilities | 9,650.10 | 4,016.60 |
| Shareholders funds | 5,300.16 | 3,065.07 |
| Share capital | 3,132.74 | 2,048.74 |
| Reserves and surplus | 2,167.42 | 1,016.33 |
| Current liabilities | 4,327.48 | 927.85 |
| Trade payables | 4,204.34 | 771.45 |
Earnings Per Share (Standalone)
- FY26 Basic EPS: ₹0.37 (before and after extraordinary items)
- FY25 Basic EPS: ₹0.04 (before and after extraordinary items)
Key Financial Figures - Consolidated (₹ in lacs)
Quarterly Performance
| Period | Revenue from Operations | Other Income | Total Revenue | Net Profit |
| Q4 FY26 (Mar 2026) | 6,835.15 | 4.67 | 6,839.81 | 98.95 |
| Q3 FY26 (Dec 2025) | 1,160.19 | 14.24 | 1,174.43 | 17.66 |
| Q4 FY25 (Mar 2025) | 2,131.94 | 14.03 | 2,145.97 | 56.97 |
Annual Performance
| Period | Revenue from Operations | Other Income | Total Revenue | Net Profit |
| FY 2025-26 | 8,988.08 | 50.92 | 9,039.00 | 131.69 |
| FY 2024-25 | 3,330.63 | 57.11 | 3,387.75 | 99.07 |
Consolidated Balance Sheet Position
| Item | As at 31-Mar-2026 | As at 31-Mar-2025 |
| Total Assets | 11,467.51 | 4,527.99 |
| Non-current assets | 5,622.74 | 2,715.03 |
| Current assets | 5,844.77 | 1,812.96 |
| Equity and Liabilities | 11,467.51 | 4,527.99 |
| Shareholders funds | 5,334.39 | 3,076.54 |
| Minority Interest | 118.53 | 109.68 |
| Current liabilities | 5,311.84 | 1,318.09 |
| Trade payables | 4,864.85 | 798.52 |
Auditor's Emphasis Matters
Emphasis 1 - Investment in Marsapi Lifesciences Private Limited
The Company made an investment of ₹16.85 crore in Marsapi Lifesciences Private Limited (100% subsidiary) during the year. The acquisition was pursuant to a Shareholders Agreement dated June 5, 2025, on a share-swap basis (no cash consideration), whereby MRC Agrotech issued 86,42,097 equity shares at ₹19.50 per share. The valuation was based on an indicative registered valuer's report.
Emphasis 2 - Agreement with Cicago Commodities Private Limited
The Company entered into an agreement with Cicago Commodities Private Limited for assignment of receivables (loans and advances totaling ₹7,30,00,978) on a non-recourse basis. Cicago Commodities agreed to settle specific trade creditor dues for the Company and paid the remaining balance to the Company. The transaction is at arm's length and in the ordinary course of business.
Key Audit Matters
1. Back-to-Back Trading Transactions
The Company executed numerous back-to-back trading transactions where purchases and corresponding sales were completed within short periods, sometimes on the same date. These transactions involved direct movement of goods through transporters and generated relatively low gross margins.
2. Year-End Concentration and Counterparty Concentration
A significant portion (44.62%) of the Company's taxable outward supplies (₹38.10 crore out of ₹85.39 crore) was recognized in March 2026. Substantial trading transactions were undertaken with two counterparties that are related to each other (though not related parties of the Company), accounting for approximately 53% of purchases and 23% of sales during the year.
3. GST Classification Issue
The Company's books recorded exempt sales of ₹81.14 crore and export sales of ₹0.06 crore, but the GSTR-3B returns filed for FY 2025-26 reflected total sales under Table 3.1(a) Outward taxable supplies without separately reporting the exempt supply. The Company explained that the goods traded are agricultural commodities classified as exempt under GST exemption notifications.
Subsidiary Information
Consolidated financial results include:
- Agronica Seeds Spark Private Limited: 51% owned subsidiary
- Marsapi Lifesciences Private Limited: 100% wholly owned subsidiary
Subsidiary financials were audited by CA Anil G Jain of Jain Anil & Associates.
Board and Committee Approvals
The financial results were reviewed by the Audit Committee and will be taken on record by the Board of Directors at their meeting scheduled for June 6, 2026.